VIA
KYMR icon

Virtus Investment Advisers’s Kymera Therapeutics KYMR Stock Holding History

Virtus Investment Advisers’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$435K Buy
3,795
+755
+25% +$64.9K 0.1% 233
2026
Q1 		$253K Buy
3,040
+74
+2% +$5.86K 0.07% 314
2025
Q4 		$231K Buy
2,966
+560
+23% +$37.8K 0.06% 358
2025
Q3 		$136K Buy
2,406
+418
+21% +$18.9K 0.04% 391
2025
Q2 		$86.8K Sell
1,988
-1,903
-49% -$65.5K 0.03% 397
2025
Q1 		$106K Buy
+3,891
New +$142K 0.03% 412

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Virtus Investment Advisers's KYMR Position: Q2 2026 in Review

Virtus Investment Advisers increased its Kymera Therapeutics (KYMR) stake by 25% in Q2 2026, buying an estimated $64.9K and bringing the position to 3,795 shares worth $435K. The position accounts for 0.1% of the portfolio, ranked #233.

Virtus Investment Advisers first reported a position in KYMR in Q1 2025 and has held it in 6 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Virtus Investment Advisers held 3,795 shares of Kymera Therapeutics worth $435K as of Q2 2026.
  • Virtus Investment Advisers bought 755 Kymera Therapeutics shares in Q2 2026, an estimated $64.9K.
  • Kymera Therapeutics made up 0.1% of Virtus Investment Advisers's portfolio in Q2 2026, its #233 holding.
  • Virtus Investment Advisers first reported a position in Kymera Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.